Note: Lancet requires free registration prior to providing access.
A. “Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial,” by David Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Dong Bok Shin, Derek Jonker, Stuart Osborne, Niko Andre, Daniel Waterkamp, and Mark P. Saunders, for the AVEX study investigators (Vol. 14, No. 11, October 2013, p. 1077-1085).
www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970154-2/abstract
B. “Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study,” by Dean Ornish, Jue Lin, June M. Chan, Elissa Epel, Colleen Kemp, Gerdi Weidner, Ruth Marlin, Steven J. Frenda, Mark Jesus M Magbanua, Jennifer Daubenmier, Ivette Estay, Nancy K. Hills, Nita Chainani-Wu, Peter R. Carroll, and Elizabeth H. Blackburn (Vol. 14, No. 11, October 2013, p. 1112-1120).
www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2813%2970366-8/abstract
